论文部分内容阅读
目的:探讨奥扎格雷钠联合脑苷肌肽治疗脑梗死(CI)患者的临床疗效。方法:选取2012年1月-2015年1月本院收治的132例CI患者随机分为对照组和研究组。所有患者均给予常规治疗,对照组采用奥扎格雷钠治疗,研究组在对照组的基础上加用脑苷肌肽,对比两组患者的血脂水平及临床疗效。结果:治疗后,研究组和对照组患者的血脂水平均有所改善,但是研究组患者的血脂水平改善更为明显,其中三酰甘油(TG)、总胆固醇(TC)水平与治疗前相比,具有统计学差异(P<0.05)。对照组和研究组患者的治疗总有效率分别为78.8%和89.4%,差异无统计学意义(P>0.05)。结论:奥扎格雷钠联合脑苷肌肽治疗CI临床疗效较好,患者的神经功能恢复较好。
Objective: To investigate the clinical efficacy of sodium ozagrel combined with cerebroside in patients with cerebral infarction (CI). Methods: A total of 132 CI patients admitted to our hospital from January 2012 to January 2015 were randomly divided into control group and study group. All patients were given conventional treatment, the control group with sodium ozagrel treatment, the study group in the control group based on the addition of cerebroside, compare the two groups of patients with blood lipid levels and clinical efficacy. Results: After treatment, the levels of serum lipids in study group and control group were all improved, but the improvement of blood lipid in study group was more obvious. The level of triglyceride (TG) and total cholesterol (TC) , With statistical difference (P <0.05). The total effective rates of the control group and the study group were 78.8% and 89.4% respectively, with no significant difference (P> 0.05). Conclusion: Ozagrel sodium combined with encephalitoside in the treatment of CI clinical effect is better, the recovery of patients with better neurological function.